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ABSTRACT
Introduction Those who are staying at home and 
reducing contact with other people during the COVID-19 
pandemic are likely to be at greater risk of medication- 
related problems than the general population. This study 
aims to explore household medication practices by and for 
this population, identify practices that benefit or jeopardise 
medication safety and develop best practice guidance 
about household medication safety practices during a 
pandemic, grounded in individual experiences.
Methods and analysis This is a descriptive qualitative 
study using semistructured interviews, by telephone 
or video call. People who have been advised to 
‘cocoon’/‘shield’ and/or are aged 70 years or over 
and using at least one long- term medication, or their 
caregivers, will be eligible for inclusion. We will recruit 100 
patient/carer participants: 50 from the UK and 50 from 
Ireland. Recruitment will be supported by our patient and 
public involvement (PPI) partners, personal networks and 
social media. Individual participant consent will be sought, 
and interviews audio/video recorded and/or detailed 
notes made. A constructivist interpretivist approach to 
data analysis will involve use of the constant comparative 
method to organise the data, along with inductive analysis. 
From this, we will iteratively develop best practice 
guidance about household medication safety practices 
during a pandemic from the patient’s/carer’s perspective.
Ethics and dissemination This study has Trinity College 
Dublin, University of Limerick and University College 
London ethics approvals. We plan to disseminate our 
findings via presentations at relevant patient/public, 
professional, academic and scientific meetings, and for 
publication in peer- reviewed journals. We will create a list 
of helpful strategies that participants have reported and 
share this with participants, PPI partners and on social 
media.
INTRODUCTION
Problem statement and knowledge gap
Medication use is the most common interven-
tion in healthcare. In the past decade, prior to 
the COVID-19 pandemic, more than 8% of all 
adult emergency hospital admissions and 25% 
of those for older adults (65 years and over) have 
been related to medication use, with increasing 
age and higher disease burden being key risk 
factors.1 2 In 2020, the world’s population is 
predicted to use 4.5 trillion medication doses, 
up 24% from 2015, and more than 50% will 
consume more than one dose per day.3 A recent 
American study identified the annual cost of 
medication- related morbidity and mortality, 
consequent to non- optimised medication use, 
as €528 billion, equivalent to 16% of healthcare 
expenditure.4 As a result of such problems, the 
current WHO Global Patient Safety Challenge 
seeks to reduce the burden of serious, avoidable 
medication- related harm by 50% within 5 years 
from 2017.5
Optimal medication use requires input from 
multiple stakeholders, including consumers, 
patients and carers, operating within complex 
adaptive systems.6 Evidence suggests that contri-
bution by patients, informal carers and family 
members (‘lay involvement’) is a potentially 
important modifiable factor in optimising 
medication outcomes and providing system 
resilience.7–10 Examples of lay involvement 
Strengths and limitations of this study
 ► This study will provide novel insights into the house-
hold medication safety practices of those who are 
cocooning/shielding during a pandemic, leading to 
the creation of best practice guidance about house-
hold medication safety practices during a pandemic 
from the patient’s/carer’s perspective.
 ► Data collection methods (telephone and video call) 
will enable us to reach vulnerable people who are 
staying at home during the pandemic, while main-
taining public health guidance for avoiding face- to- 
face contact.
 ► Because interviews are limited to the English lan-
guage, the perspectives of people who do not 
speak English confidently are likely to be under- 
represented. In addition, the perspectives of those 
without telephone or internet access will not be 
obtained.
 ► It is possible that theoretical saturation may not be 
reached due to resource constraints, which limit 
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include patients and family members routinely taking on 
medication management roles,9 11–13 often of complex medi-
cation regimens and in challenging contexts, such as in 
dementia,14–16 heart failure,17 chronic obstructive pulmonary 
disease,18 cancer19 and home palliative care.20 However, there 
are known hazards in lay medication practices, including 
errors in medication administration,9 sharing or borrowing 
prescribed medication,21 22 unsafe or unsuitable storage23 24 or 
disposal,19 hoarding,17 25 stockpiling17 and non- adherence.26 
Therefore, there is much to address before the full potential 
of lay involvement in safe household medication use can be 
realised.
The literature suggests that medication use poses a signif-
icant body of medication- related ‘work’ for lay users.11 17 18 27 
Specifically, this suggests that patients themselves manage the 
majority of their medication work, but that a proportion is 
managed by others who are members of the person’s social 
network.11 Explorations of the nature of lay work involved in 
medication practices, whether for self or others, have identi-
fied a range of strands to this work. The work includes plan-
ning and coordination of medication taking and adherence, 
emplacement of medication in the home or other personal 
spaces, tracking of medication supplies, monitoring of effects 
of medication use, monitoring for and management of one’s 
own or others’ errors, management of information from 
professional or non- professional and personal sources and 
interactions between all of these.11 17 18 27–29 Several studies 
identify that lay medication work involves an emotional 
burden, often associated with a response to the need to use 
or rely on medication, the toll of the work involved and the 
response to one’s own or another’s efforts around medica-
tion adherence.11 17 18 27 28 Medication use has been identi-
fied as a tool to facilitate a person to (re)gain control in the 
personal context of a relatively less controlled or chaotic 
experience of illness.11 17 There is evidence that medica-
tion taking and medication work are highly personalised 
and complex phenomena that may be contingent on, and 
contextualised by one’s situation, environment, processes 
and network.11 17 30 Examples of such complexities include 
the medication user’s individualised routines and strategies, 
the nature of medication(s) involved, the range of people 
involved or the individual’s illness burden.11 Studies have 
identified that medication work comprises sociotechnical 
efforts that are often complex,17 and that lay people develop, 
adapt and rely on a variety of strategies to achieve personal 
goals associated with medication use.11 17 18 29 30
In their study of older adults with heart failure, Mickelson 
et al argue that medication management is the most common 
performed self- care behaviour in this cohort.17 Cheraghi- 
Sohi et al11 developed a framework of ‘medication work’ 
using social network analysis to map the work undertaken 
by people with long- term conditions (LTCs) and their wider 
social networks, that is, people identified in some way to be of 
relevance to the person’s medication management.11 Schaf-
heutle et al subsequently applied and adapted this frame-
work to people experiencing chronic obstructive pulmonary 
disease.18 Both Cheraghi- Sohi et al’s and Schafheutle et al’s 
studies were based on interviews undertaken with people with 
LTCs and therefore provide the patient’s/carer’s perspective, 
which is also central to the present work.11 18 However, this 
body of evidence has been generated outside of the context 
and constraints of a pandemic and studies have not exam-
ined populations staying at home for long periods.
During the COVID-19 pandemic, people who are self- 
isolating and housebound for long periods of time, whether 
due to age or ‘extreme medical vulnerability’, are potentially 
at increased risk of medication- related problems or harm. 
These may include medication errors, adverse drug reac-
tions, adverse drug events and medication non- adherence. 
The key clinical issues with the potential to affect medication 
safety for those who are self- isolating for long periods of time 
during the COVID-19 pandemic are: (1) disrupted routine 
healthcare services and supply chains; (2) altered household 
mobility, well- being and support structures; (3) reluctance 
to attend healthcare or restrictions on attending healthcare 
and (4) misinformation about medications reported to affect 
the risk or severity of COVID-19 infection. These create addi-
tional challenges for standard medication safety, at a time 
when prevention of avoidable iatrogenic harm is particularly 
important.
The present need for research
Relatively little is known about medication safety or changes to 
household medication practices during a pandemic. Limited 
evidence on medication use during previous pandemics 
identifies reduced health- seeking behaviour from clinics or 
hospitals, increased self- management of common or chronic 
ailments at home, increased self- medication, stockpiling 
antiviral medication and increased attendance at emergency 
departments for antiviral related adverse effects.31–34 Disrup-
tion of household mobility, well- being and social network 
membership is likely for people who are staying at home 
and self- isolating during the COVID-19 pandemic. This 
disruption therefore has the potential to affect medication 
work and practices, and to alter routine defences or hazards, 
thereby affecting medication safety.
Previous studies have generally classified drug- related 
problems from a healthcare professional’s perspective, rather 
than that of the person taking the medication or their social 
network; drug- related problems are also generally identified 
in the context of medication review, rather than routine 
household settings.35 The patient’s perspective of household 
medication use is central to the present study. The patient- 
centred medication safety framework is grounded in the 
patient’s perspective of matters that they consider important 
to the management of medication safety incidents in primary 
care.8 However, it does not address the broader concept of 
household medication safety practices, which is the focus of 
the current study.
Evidence supports the combined use of Safety- I and Safe-
ty- II approaches to identify when, where, how and why things 
go wrong (Safety- I) or right (Safety- II).36 Medication prac-
tices occur within complex sociotechnical systems where 
people (agents and actors), artefacts, information and knowl-
edge flows, technologies, environments and individual or 
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way.6 17 37 38 A Safety- I/Safety- II perspective has previously 
been used to understand and create frameworks of hazards 
and defences associated with routine medication practices 
in the community,8 hospital38 and domiciliary settings,12 39 
involving medication safety incidents, intravenous infusion 
practices, informal carer medication administration and 
domiciliary medication safety among caregivers of chron-
ically ill children. Mickelson et al used a systems engineering 
framework to support their analysis of medication manage-
ment strategies by older patients with heart failure.17 We are 
not aware of any study that has employed Safety- I/Safety- II 
approaches to support the analysis of household medication 
safety practices among either the general adult population or 
those who are housebound, or in the context of a pandemic.
This study therefore seeks to explore household medi-
cation practices for people who are staying at home and 
reducing contact with others as much as possible during the 
COVID-19 pandemic. It also aims to create best practice guid-
ance about household medication safety practices during a 
pandemic from the patient’s/carer’s perspective, which can 
be used to enable patient and carer agency in safe medica-
tion practices during the COVID-19 pandemic and beyond.
Specific objectives are to:
 ► Explore experiences of patients (or their carers) 
around household medication safety practices during 
the pandemic.
 ► Identify practices and situations that may benefit or 
jeopardise medication safety practices during the 
pandemic.
 ► Create best practice guidance about household medi-
cation safety practices during a pandemic from the 
patient/carer perspective.
METHODS AND ANALYSIS
Researcher characteristics and reflexivity
The research team is composed of research pharma-
cists working in the academic setting (TCG, DK), and 
hospital and academic settings (BDF, SG), an organi-
sational psychologist (SC) and senior researchers with 
expertise in human factors, well- being management and 
older adult enablement (JC) and health services research 
(CW). Patient and public involvement (PPI) partners will 
also be involved in data analysis.
Context
We will conduct the study in the four devolved nations of the 
UK, and Ireland. All have implemented public health guid-
ance to protect those who are extremely medically vulner-
able during the COVID-19 pandemic. This includes advice 
for such people to stay at home as much as possible and 
reduce contact with other people, referred to as ‘cocooning’ 
in Ireland and ‘shielding’ in the UK.40 41
Design
Qualitative exploration using semistructured interviews. 
Qualitative methods are central to exploring medication 
practices and medication safety, and have been used for this 
purpose in both domiciliary and hospital settings.8 12 38 39
Definition of household medication safety practices
We define household medication safety practices as any activ-
ities by patients, their caregivers or members of their social 
networks related to obtaining supplies, deciding whether or 
not to use medicines, storing, consuming or administering 
medication, monitoring and responding to signs of ther-
apeutic or adverse effects. We include prescribed, over- the- 
counter, complementary and alternative medication.
Participants
Inclusion criteria
Adults will be eligible to participate if they experience a 
medical vulnerability listed on the government public health 
advice as requiring protection against COVID-19 infection 
and have been advised to ‘shield’40 or ‘cocoon’41 during the 
COVID-19 pandemic, and/or are aged 70 years or more, and 
they use at least one long- term medication. Carers who assist 
in the medication management of an adult who fulfils these 
two criteria are also eligible to take part.
Exclusion criteria
 ► Children under 18 years of age.
 ► People too unwell or otherwise unable to consent to 
interview.
 ► People not speaking English confidently.
 ► People without access to a telephone or a device with 
internet connection.
Sampling strategy
Up to 100 adult research participants will be selected using 
convenience sampling, to include patients and carers living in 
the UK or Ireland. Our protocol does not include a screening 
procedure to assess the demographic or clinical characteris-
tics of prospective research participants prior to study recruit-
ment. However, following recruitment, we will create a matrix 
of brief background demographic characteristics of those 
previously interviewed to support iterative, focused recruit-
ment of a diverse sample. We aim for the study population 
to represent people with a range of ages, genders, ethnicities, 
geographical areas, number of medicines and living alone or 
with others and those who are patients or carers.
Recruitment
Research participants will be recruited through patient or 
carer advocacy groups or charities, by engaging with our PPI 
partners, personal or professional networks and through 
social media. Our focused recruitment will also support us 
to recruit a diverse sample of people with differing at- home 
medication needs and roles. For example, we will do focused 
recruitment of those in carer roles, by engaging with our 
PPI partners in carer advocacy groups. We will do focused 
recruitment of those experiencing particular medical vulner-
abilities by engaging with charities and PPI partners working 
in that context, for example, cystic fibrosis, arthritis, cancer, 
organ transplant and old age. Prospective participants will be 
encouraged to make contact with a member of the research 
team, by telephone or email. Consistent with ethical, data 
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third parties to pass prospective participants’ personal details 
to the research team.
Data collection
We will use semistructured interviews conducted by tele-
phone or video call. Data will be collected from June 
through October 2020. Patients will be invited to express 
their preferred mode of data collection. We aim to inter-
view 50 participants in Ireland and 50 in the UK. With the 
participant’s consent, interviews will be audio or audio–video 
recorded and/or the researcher will take detailed notes.
Interview
A member of the research team will conduct the interview at 
a pre- agreed date and time. The interview will explore medi-
cation use by the patient participant or for the person(s) to 
whom a carer participant provides care. This interview will 
occur remotely using the participant’s preferred method of 
telephone or video call. At no stage will the researcher and 
participant meet in person. Interviews are expected to last 
15–45 min.
The proposed topic guide (box 1) was developed using 
a priori principles of routine lay medication use, applied in 
the context of the COVID-19 pandemic. Interviewers will use 
additional prompts and follow- up questions as needed.
Data processing
Interview recordings will be transcribed verbatim (either 
automated or using a third- party service) and merged with 
the researcher notes. Any identifiable information will be 
redacted from the transcription. The recording will be perma-
nently deleted at a time consistent with the ethics approval 
and data protection regulations in each country. The tran-
scribed files will be imported into NVivo to support data anal-
ysis. We will restrict access to the identifiable interview files to 
the research team at each site (Dublin, Limerick or London). 
Following irreversible anonymisation, the data collected by 
the researcher(s) at each university will be processed and 
analysed at that university and may be transferred among 
them at the later stages of analysis to support comparison in 
line with ethical approvals.
Analysis
A constructivist–interpretive analysis approach will be used. 
The constant comparative technique will be employed to 
systematically organise, compare and understand similar-
ities and differences in the data.42 Data analysis will occur 
in parallel to data collection. Inductive analysis will be used 
to identify the emergent medication practices, strategies, 
hazards and defences. Sociotechnical assessment approaches 
using a Safety- I/Safety- II perspective36 and Schafheutle et 
al’s medication work framework18 will serve as sensitising 
concepts43 to explore the data, in which their application will 
be used to inspire insights appropriate to the data rather than 
being used as a rigid coding framework. This will support the 
iterative development of our best practice guidance about 
household medication safety practices relating to those who 
are staying at home for long periods during a pandemic.
Research rigour, trustworthiness and credibility
We used the Standards for Reporting Qualitative Research 
recommendations to guide this protocol development.44 
In Ireland, research participants will be offered access to 
the recorded interview file, researcher notes or transcrip-
tion. Member checks of these files are welcome but are not 
required. Each interviewer will quality assure their own inter-
views for transcription accuracy. A proportion of interviews 
will be coded independently by at least two members of the 
research team, followed by a comparison of and discussion 
of coding as a means to quality assure the coding process. 
Publication of this protocol is our first step in documenting 
and creating an audit trail of decisions made throughout the 
project and we will continue to capture these during data 
collection, analysis and reporting.
Patient and public involvement
PPI will be facilitated through personal and professional 
networks, contacts within patient advocacy groups, chari-
ties and professional organisations. PPI commenced during 
the development phase by partners, including patients, 
validating our research aim and reviewing all participant- 
facing materials including recruitment materials, participant 
information leaflet, consent form and interview topic guide. 
Research participant recruitment will be supported by our 
PPI partners in patient and carer advocacy groups and other 
networks. PPI will extend to consultation on dissemination 
and outreach activities and involvement with data analysis 
and interpretation, using models employed previously.45 46 
All PPI will occur remotely, compliant with current public 
health advice for avoiding face- to- face contact. Our PPI part-
ners will be offered the opportunity to coauthor the future 
papers describing our research findings.
Ethical considerations
Approval for this study was granted by the Trinity College 
Dublin Faculty of Health Sciences Research Ethics Committee 
(reference COVID-19 2020502), University of Limerick 
Education and Health Sciences Research Ethics Committee 
(reference 2020_06_08_EHS) and University College 
London Research Ethics Committee (reference 18417.001). 
Box 1 Topic guide
1. Before the coronavirus pandemic, how did you get on managing 
your medicines, or the medicines for the person(s) to whom you 
provide care?
2. Since the coronavirus pandemic started, how has the way you man-
aged or used medicines changed?
3. Have you experienced any difficulty using or managing medication 
during the pandemic?
4. What do you think would make it easier or better to manage medi-
cations at home during the pandemic?
5. What would you advise others to do in your situation?
6. Do you have anything else you would like to add?
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The legal basis, in Ireland and the UK, for the processing of 
these data is scientific research in the public interest, however, 
we will invite informed consent from all participants prior 
to participation. In the context of the COVID-19 pandemic 
and infection control of this medically vulnerable group, 
verbal consent by audio- recorded telephone or video call, 
in cases where hard copy postage or electronic transmission 
poses a challenge, has been deemed acceptable by the ethics 
committees concerned. Compliant with contemporary data 
protection guidance for qualitative research during COVID-
19, recordings of interviews will be permanently deleted as 
soon as specified in the ethics application at each site and 
transcripts will be irreversibly anonymised. As with all qualita-
tive research, quotations from interviews will be used to illus-
trate the findings and, in all cases, will be anonymised and of 
a nature that cannot be traced back to any given person. If 
interviewers identify any pressing medication safety concerns, 
they will signpost the participant to relevant sources of 
support.
Dissemination
We plan to present our work at suitable Irish, UK and interna-
tional conferences and to publish at least one peer- reviewed 
research paper. We will produce plain English summaries of 
our work, which we will offer to send to participants, and we 
will engage with our PPI partners to optimise public outreach 
and research impact to the wider public. We will disseminate 
to healthcare professionals through professional bodies. We 
will produce a policy brief outlining key recommendations 
to support safer lay medication practices among those who 
are housebound in the context of a pandemic. Our research 
paper(s) will be made available open access and the summa-
ries will be shared through our university repositories and 
social media channels, and through our PPI partners’ social 
media channels.
Impact
The proposed output from this research is a set of best prac-
tice guidance about household medication safety practices 
during a pandemic from the patient’s/carer’s perspective, 
relating to those who are staying at home and reducing 
contact with others as much as possible during the COVID-19 
pandemic. We will create a list of helpful strategies that 
participants have reported and share this with participants, 
PPI partners and on social media, to use as a tool to enable 
agency and medication safety at home for people who are 
shielding, cocooning or equivalent during a pandemic.
The research priorities outlined in the WHO and Global 
Research Collaboration for Infectious Disease Prepared-
ness joint research roadmap for the COVID-19 pandemic 
include: to rapidly identify secondary effects of the outbreak 
and deliver strategies to mitigate patient harm, and to rapidly 
involve communities in the design, delivery and dissemi-
nation of research.47 The proposed study addresses both 
priorities by providing person- centred guidance, based on 
individual experiences, with significant PPI input. Enabling 
patients, carers and social network members to become 
agents in medication safety aligns with the WHO agreed 
global priorities for medication safety research.48 Future work 
will explore the transferability of this guidance to a wider 
population of housebound and ambulatory people who are 
using medication long term, and outside of the context of a 
global pandemic. Given the forecasted increase in the global 
population of adults living well with age- related conditions 
over the coming decades,49 an important consideration is to 
enable people to remain in their homes and to be agents in 
their own medication management and safety.50 51
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